Skip to main content
SpringerLink
Log in

Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Cinacalcet has been shown to be effective in lowering serum intact parathyroid hormone (iPTH) levels in patients with advanced secondary hyperparathyroidism (SHPT). We investigated clinical factors influencing therapeutic response to cinacalcet for SHPT refractory to active vitamin D sterols.

Methods

A total of 57 hemodialysis patients with SHPT (iPTH >300 pg/mL) were enrolled in this 28-week, prospective, observational study. Cinacalcet was started at an initial dose of 25 mg/day; the dose of cinacalcet was titrated to achieve the following: 3.5 ≤ phosphate (P) ≤ 6.0 mg/dL; 8.4 ≤ adjusted calcium (Ca) ≤ 10.0 mg/dL; 60 ≤ iPTH ≤ 180 pg/mL). Parathyroid ultrasonographic examination was performed at the start of cinacalcet treatment. Patients were divided into two groups on the basis of iPTH levels after 28 weeks: Group A, iPTH ≤180 pg/mL; Group B, iPTH >180 pg/mL.

Results

Serum iPTH and P levels at baseline were significantly higher in Group B than Group A. The number of enlarged parathyroid glands (PTGs) (estimated volume ≥500 mm3 or major axis ≥10 mm), which presumably had nodular hyperplastic lesions, and the largest and the total volume of detectable PTGs were significantly greater in Group B compared with Group A. In our multivariate logistic regression analysis, patients with two or more enlarged PTGs had a significant risk of poor response to cinacalcet treatment (odds ratio 5.68, 95% confidence interval 1.19–32.66, P = 0.0363).

Conclusion

These results indicate that the number of enlarged PTGs could predict therapeutic response of cinacalcet in patients with advanced SHPT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Akizawa T, Kamimura M, Mizobuchi M, Shiizaki K, Sumikado S, Sakaguchi T, Negi S, Ogata H, Kinugasa E. Management of secondary hyperparathyroidism of dialysis patients. Nephrology (Carlton). 2003;8(Suppl):S53–7.

    Article  CAS  Google Scholar 

  2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.

    Article  PubMed  CAS  Google Scholar 

  3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–8.

    PubMed  CAS  Google Scholar 

  4. Ogata H, Koiwa F, Kinugasa E, Akizawa T. CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol. 2007;11:261–8.

    Article  PubMed  CAS  Google Scholar 

  5. Fukagawa M, Nakanishi S, Fujii H, Hamada Y, Abe T. Regulation of parathyroid function in chronic kidney disease (CKD). Clin Exp Nephrol. 2006;10:175–9.

    Article  PubMed  CAS  Google Scholar 

  6. Goto N, Tominaga Y, Matsuoka S, Sato T, Katayama A, Haba T, Uchida K. Cardiovascular complications caused by advanced secondary hyperparathyroidism in chronic dialysis patients; special focus on dilated cardiomyopathy. Clin Exp Nephrol. 2005;9:138–41.

    Article  PubMed  Google Scholar 

  7. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008; 12:514–525.

  8. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42:S1–S201.

    Google Scholar 

  9. Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, Tominaga Y, Iseki K, Tsubakihara Y. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial. 2008;12:49–54.

    Article  PubMed  CAS  Google Scholar 

  10. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–25.

    Article  PubMed  CAS  Google Scholar 

  11. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–800.

    Article  PubMed  CAS  Google Scholar 

  12. Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transpl. 2008;23:328–35.

    Article  CAS  Google Scholar 

  13. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63:248–54.

    Article  PubMed  CAS  Google Scholar 

  14. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14:575–83.

    Article  PubMed  CAS  Google Scholar 

  15. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4:643–6.

    Article  PubMed  CAS  Google Scholar 

  16. Kimata N, Miwa N, Otsubo S, Iwasaki T, Yabuki Y, Miyabe K, Asamiya Y, Sato K, Sugi O, Ikebe N, Kiuchi K, Mineshima M, Akiba T. Achievement of the Japanese Society for Dialysis Therapy guideline targets for mineral metabolism measures: one Japanese university center result. Ther Apher Dial. 2007;11(Suppl 1):S62–6.

    Article  PubMed  CAS  Google Scholar 

  17. Komaba H, Igaki N, Takashima M, Goto S, Yokota K, Komada H, Takemoto T, Kohno M, Kadoguchi H, Hirosue Y, Goto T. Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines. Ther Apher Dial. 2008;12:42–8.

    Article  PubMed  CAS  Google Scholar 

  18. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760–71.

    Article  PubMed  CAS  Google Scholar 

  19. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009;94:4860–7.

    Article  PubMed  CAS  Google Scholar 

  20. Unbehaun R, Lauerwald W. Successful use of cinacalcet HCl in a patient with end-stage renal failure and refractory secondary hyperparathyroidism due to parathyromatosis. Clin Nephrol. 2007;67:188–92.

    PubMed  CAS  Google Scholar 

  21. Komaba H, Fukagawa M. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Ther Apher Dial. 2008;12(Suppl 1):S44–9.

    Article  PubMed  CAS  Google Scholar 

  22. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994;68:221–8.

    Article  PubMed  CAS  Google Scholar 

  23. Katoh N, Nakayama M, Shigematsu T, Yamamoto H, Sano K, Saito I, Nakano H, Kasai K, Kubo H, Sakai S, Kawaguchi Y, Hosoya T. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis. 2000;35:465–8.

    Article  PubMed  CAS  Google Scholar 

  24. Douthat WG, Orozco SE, de Arteaga J, Massari PU. Treatment of refractory secondary hyperparathyroidism with ethanol injection: the importance of glandular volume. Kidney Int Suppl. 2003;85:S101–S4.

    Google Scholar 

  25. Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, Izumotani T, Yamakawa T, Imanishi Y, Shoji T, Inaba M, Nishizawa Y. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transpl. 2003;18:2613–21.

    Article  CAS  Google Scholar 

  26. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:78–86.

    Article  PubMed  CAS  Google Scholar 

  27. Tominaga Y, Inaguma D, Matsuoka S, Tahara H, Kukita K, Kurihara S, Onoda N, Tsuruta Y, Tsutsui S, Ohta K, Kuwahara M, Tanaka M, Nishizawa Y. Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial. 2006;10:198–204.

    Article  PubMed  CAS  Google Scholar 

  28. Fukagawa M, Kitaoka M, Inazawa T, Kurokawa K. Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Curr Opin Nephrol Hypertens. 1997;6:349–55.

    Article  PubMed  CAS  Google Scholar 

  29. Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S, Maeda S, Kitazawa R. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 2000;58:1980–6.

    Article  PubMed  CAS  Google Scholar 

  30. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328–36.

    Article  PubMed  CAS  Google Scholar 

  31. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436–43.

    Article  PubMed  CAS  Google Scholar 

  32. Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol. 2004;15:2579–87.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuzuki, Yokohama, Kanagawa, 2248503, Japan

    Masahiro Yamamoto, Hiroaki Ogata, Noriyo Yoshida & Eriko Kinugasa

  2. Department of Nephrology, Showa University School of Medicine, Tokyo, Japan

    Masahide Mizobuchi & Chiaki Kumata-Maeta

  3. Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan

    Fumihiko Koiwa

  4. Internal Medicine, Sekishin-kai Kawasaki Clinic, Kawasaki, Japan

    Kanji Shishido

Authors
  1. Masahiro Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroaki Ogata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahide Mizobuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noriyo Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chiaki Kumata-Maeta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fumihiko Koiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kanji Shishido
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eriko Kinugasa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroaki Ogata.

About this article

Cite this article

Yamamoto, M., Ogata, H., Mizobuchi, M. et al. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism. Clin Exp Nephrol 16, 292–299 (2012). https://doi.org/10.1007/s10157-011-0547-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-011-0547-5

Keywords

Search

Navigation